Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

TM-REST · A new platform for fast molecular detection of MDR and XDR resistant strains of M. tuberculosis and of drug resistant malaria

FP7Status: CLOSED1 January 200830 June 2011EU funding €2,983,207

Recent developments in molecular tools combined with updated epidemiological data provide novel challenges to the development of modern molecular diagnostics. The increasing threat of infections due to Mycobacterium tuberculosis, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections poses important questions that call for development of integrated tools for rapid diagnosis. In the specific case of tuberculosis (TB), an integrated rapid diagnostic approach should be able to allow at the same time species identification, drug susceptibility testing and molecular typing. We propose to develop and validate a silicon-based platform for molecular biology testing consisting in a single disposable device (biochip) and on associated specific instruments (reader). This technology is able to simultaneously serve as a platform for high specificity amplification and hybridisation of selected targets, and to provide the diagnostic report within few hours. Main advancement over existing technology (i.e. Real-Time PCR) consists in the possibility to perform the test at competitive costs, using an higher number of genetic probes by integrating multiple, separate PCR chambers and medium density array (50-200 probes), with faster and more stable amplification and hybridisation reactions through optimised and controlled thermal ramps and profile. In addition to the technology development, special focus will be put on the feasibility and cost-effectiveness of such a novel tool with high technological content for application in countries with high TB, MDR- and XDR-TB incidence. In parallel to the development and validation of the chip-based diagnostic platform for TB, a feasibility study on its applicability to other poverty related diseases such as malaria, will be carried out. In summary, the present proposal aims at developing an affordable, high-tech platform for rapid molecular diagnosis applicable to TB and other infectious and poverty-related diseases

Consortium · 9 organisations

coordinator

FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

IT · €525,799

participant

UNIVERSITA DEGLI STUDI DI SIENA

IT · €306,000

participant

NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES

BG · €90,000

participant

FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS

CH · €300,000

participant

QENDRA SPITALORE RAJONALE E TIRANES SHEFQET NDROQI

AL · €90,000

participant

QUEEN MARY UNIVERSITY OF LONDON

UK · €685,415

participant

UNIVERSITY OF GLASGOW

UK · €389,373

participant

STMICROELECTRONICS SRL

IT · €284,077

participant

FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM

DE · €312,543

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.